Cargando…

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy

Detalles Bibliográficos
Autores principales:	Chen, Jie Qing, Creasy, Caitlin, Cabala, Carlos Antonio Torres, Ekmekcioglu, Suhendan, Maiti, Sourindra N, Roszik, Jason, Haymaker, Cara, Bernatchez, Chantale, Hwu, Patrick, Radvanyi, Laszlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990992/ http://dx.doi.org/10.1186/2051-1426-1-S1-P48

Ejemplares similares

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jieqing, et al.
Publicado: (2014)

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
por: Forget, Marie-Andrée, et al.
Publicado: (2015)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
por: Haymaker, Cara L, et al.
Publicado: (2015)

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy
por: Forget, Marie-Andrée, et al.
Publicado: (2013)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Immediate triggering of 4-1BB co-stimulation during initiation of tumor-infiltrating lymphocyte (TIL) expansion from melanoma tumors accelerates CD8+ T-cell outgrowth and tumor specificity
por: Chacon, Jessica, et al.
Publicado: (2013)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
por: Nguyen, Linh T., et al.
Publicado: (2010)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
por: Poch, Michael, et al.
Publicado: (2018)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
por: Zhao, Yueshui, et al.
Publicado: (2022)

Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
por: Jiménez-Reinoso, Anaïs, et al.
Publicado: (2021)

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
por: Fanale, Daniele, et al.
Publicado: (2022)

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
por: Fix, Samantha M, et al.
Publicado: (2022)

Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
Publicado: (1996)

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
por: Kos, Zuzana, et al.
Publicado: (2020)

Editorial: Targeting Metabolism in Cancer Immunotherapy
por: Roszik, Jason, et al.
Publicado: (2018)

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells
por: Caraban, Bogdan Marian, et al.
Publicado: (2023)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

Targeting iNOS to increase efficacy of immunotherapies
por: Ekmekcioglu, Suhendan, et al.
Publicado: (2017)

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder
por: Eismann, Lennert, et al.
Publicado: (2022)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer
por: Liao, Rong, et al.
Publicado: (2021)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma
por: Meng, Qingda, et al.
Publicado: (2015)

The Relationship between Tumor-infiltrating Lymphocytes (TILs) and Nasopharyngeal Carcinoma (NPC): A Systematic Review
por: Prasetyo, Awal, et al.
Publicado: (2021)

Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients
por: Vaid, Pooja M., et al.
Publicado: (2022)

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
por: Tas, Liselotte, et al.
Publicado: (2023)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3trq51e0k5lpn509mhvlnjrvug